Exelixis
Large Cap · Healthcare · Biotechnology
$53.14+$0.82 (+1.57%)
Exelixis
Large Cap · Healthcare · Biotechnology
$53.14+$0.82 (+1.57%)
Stock analysis
Get the AI take on EXEL
Track it to unlock the price chart, verdict and what could change it.
- ✓Live price chart
- ✓A clear accumulate, trim or avoid call
Free to track. No card required.
Stock Fundamentals & Key Indicators
52-week range
Low$33.76
High$57.57
Today $53.14
RSI (14)
44.3Neutral
03070100
Overall score
69/100
See the full financial picture
Open the five-year record, valuation checks and Wall Street view behind these scores.
- ✓5 years of revenue, profit and cash flow
- ✓Valuation and balance-sheet checks
- ✓Business and geographic mix
- ✓Analyst targets and recommendation trend
Free for 3 days, then $9/mo. Cancel anytime.
Analyst Rating and Sentiment
Analyst price targets
Lowest
$41
Median target
$52
Current price
$53.14
Highest
$66
LowHigh
Operating Record
Revenue
What's working
- Cash exceeds debt by $1.2B, leaving a net cash buffer, a good sign.
- Forward P/E: Investors aren't pricing in much earnings growth, so there's room to be pleasantly surprised.
What the market charges
Forward P/E
Favorable · 25% below avg
14.68x
Price / sales
Reasonable · Priced reasonably against its revenue
5.21x
Price / FCF
Strong · Priced well within what its cash flow supports
10.83x
EV / EBITDA
Strong · Operating earnings comfortably support this price
11.25x
How efficiently it compounds
ROIC
Strong · Comfortably clears the bar for efficient capital use
66.0%
ROE
Favorable · 41.0% - strong capital efficiency
44.4%
Debt / equity
Favorable · 0.09 - strong leverage
0.09x
Current ratio
Strong · Comfortable room to cover bills due within a year
3.46x
Peer Comparison
| Company | Mkt cap | P/E | Rev growth | Score |
|---|---|---|---|---|
| $12.70B | 16.1 | +9.2% | 69 |
 | $11.53B | 22.0 | +19.7% | 78 |
 | $4.60B | 13.9 | +13.5% | 77 |
 | $33.87B | 35.4 | +15.5% | 77 |
 | $1.11T | 40.1 | +49.6% | 76 |